Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled time : 22:15 save search
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
Published: 2020-05-14 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 11.11%
H: 0.2%
C: -9.78%
results
Onconova Therapeutics Announces Presentation at BIO Digital 2020
Published: 2020-06-08 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.33%
H: 6.69%
C: -0.06%
presentation therapeutics
Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)
Published: 2020-06-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.97%
H: 9.68%
C: -2.11%
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.79%
H: 6.33%
C: 2.38%
treatment phase 3 phase 1 phase 2 nivolumab
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
Published: 2020-06-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.37%
H: 0.79%
C: -3.97%
therapeutics market
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
Published: 2020-07-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.07%
H: 4.7%
C: 2.69%
risk results leukemia research phase 3 phase 1 phase 2
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
Published: 2020-07-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 6.72%
H: 2.36%
C: -10.24%
therapy cancer preclinical pre-clinical
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
Published: 2020-07-27 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 12.61%
H: 0.0%
C: -0.8%
covid disease application
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
Published: 2020-07-29 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.77%
H: 24.32%
C: 15.32%
phase 3 trial
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement
Published: 2020-08-04 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -2.63%
H: 2.7%
C: -0.9%
therapeutics nasdaq
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
Published: 2020-08-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -3.29%
H: 11.65%
C: 10.68%
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
Published: 2020-08-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: -3.81%
results
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
Published: 2020-08-24 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -72.75%
H: 44.62%
C: 24.6%
results phase 3 trial topline
Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
Published: 2020-08-31 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.04%
H: 0.77%
C: -12.12%
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
Published: 2020-09-09 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.0%
H: 7.52%
C: 5.01%
therapeutics
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Published: 2020-09-21 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 24.3%
H: 9.9%
C: -9.03%
china biopharma trial phase 3 phase 1 phase 2
Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
Published: 2020-10-13 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.67%
H: 25.74%
C: 23.64%
Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
Published: 2020-11-05 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -0.2%
H: 4.97%
C: 2.23%
results
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Published: 2020-11-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -8.36%
H: 0.97%
C: -1.08%
results
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Published: 2020-11-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: -2.82%
drug new drug application
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.